Skip to main content
. 2022 Apr 29;10(5):1026. doi: 10.3390/biomedicines10051026

Table 2.

Impact of Vaccination and MoAbs administration on COVID-19 course during the second year of pandemic (84 SARS-CoV-2-infected PADs patients).

Hospitalization n (%) Unadjusted
OR (95% CI)
Adjusted
OR (95% CI)
Vaccinated vs. not vaccinated 9 (15.5) vs. 6 (24.0) 0.582 (0.182–1.857) p = 0.360 * 0.453 (0.131–1.561) p = 0.210 §
MoAbs vs. not MoAbs 6 (10.7) vs. 9 (32.1) 0.253 (0.079–0.808) p = 0.020 * 0.187 (0.053–0.653) p = 0.009 #
Severe Disease n (%) Unadjusted
OR (95% CI)
Adjusted
OR (95% CI)
Vaccinated vs. not vaccinated 3 (5.2) vs. 2 (8.0) 0.627 (0.098–4.006) p = 0.622 * 0.664 (0.096–4.564) p = 0.677 §
MoAbs vs. not MoAbs 1 (1.8) vs. 4 (14.3) 0.109 (0.012–1.028) p = 0.053 * 0.095 (0.009–0.951) p = 0.045 #
Mortality n (%) Unadjusted
OR (95% CI)
Adjusted
OR (95% CI)
Vaccinated vs. not vaccinated 2 (3.4) vs. 1 (4) 0.857 (0.074–9.909) p = 0.902 * 0.781 (0.059–10.294) p = 0.851 §
MoAbs vs. not MoAbs 1 (81.8) vs. 2 (7.1) 0.236 (0.020–2.726) p = 0.248 * 0.110 (0.013–2.147) p = 0.167 #

* Binomial logistic regression analysis. § Adjusted for age and gender by multivariable logistic regression analysis. # Adjusted for age, gender, and vaccination status by multivariable logistic regression analysis.